Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.

开始日期2026-09-01

申办/合作机构

厦门大学附属第一医院（厦门市第一医院、厦门市红十字医院、厦门市糖尿病研究所）

NCT07833241

/ Not yet recruiting临床2期IIT

Neoadjuvant Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for High-risk Resectable or Borderline Resectable Pancreatic Cancer: a Single-arm, Single-center, Exploratory Clinical Study

This is a prospective, single-center, single-arm phase 2 study evaluating the efficacy and safety of neoadjuvant surufatinib plus iparomlimab and tuvonralimab injection and nab-paclitaxel/gemcitabine chemotherapy in patients with high-risk resectable or borderline resectable pancreatic cancer. Approximately 56 participants will be enrolled, including about 19 patients with high-risk resectable disease and 37 patients with borderline resectable disease. Participants will receive up to four 21-day cycles of neoadjuvant treatment. Participants considered eligible for surgery will undergo surgical resection approximately 4 weeks after neoadjuvant treatment. After surgery, adjuvant chemotherapy with either gemcitabine plus capecitabine or modified FOLFIRINOX will be selected by the investigators after multidisciplinary team review. The primary outcome is the 12-month event-free survival rate.

开始日期2026-09-01

申办/合作机构

复旦大学附属中山医院

NCT07609121

/ Recruiting临床2期IIT

A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

This phase II trial employs a prospective, randomized, parallel-group design to evaluate the efficacy and safety of hypofractionated radiotherapy combined with tislelizumab and surufatinib. Eligible patients are randomly assigned to one of two arms: Experimental Group A receives hypofractionated chemoradiotherapy plus concurrent tislelizumab and surufatinib, followed by consolidation therapy with tislelizumab plus surufatinib; Experimental Group B receives the same hypofractionated chemoradiotherapy plus concurrent tislelizumab alone, followed by tislelizumab consolidation.

开始日期2026-06-01

申办/合作机构

中山大学

100 项与索凡替尼相关的临床结果

登录后查看更多信息

100 项与索凡替尼相关的转化医学

登录后查看更多信息

100 项与索凡替尼相关的专利（医药）

登录后查看更多信息

项与索凡替尼相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer

Article

作者: Lin, Peicheng ; Wei, Shenghong ; Su, Liyu ; Li, Hui ; Zheng, Liang ; Zhao, Shen ; Zhuo, Changhua ; Yu, Shichao ; Hong, Yanni ; Chen, Ying ; Yin, Yi ; Ye, Zaisheng ; Lin, Rongbo ; Li, Jinluan

BACKGROUND:

Second-line treatment for metastatic colorectal cancer (mCRC) typically involves oxaliplatin- or irinotecan-based doublet chemotherapy with or without anti-angiogenic antibodies. Triplet regimens such as FOLFOXIRI have demonstrated synergy and improved efficacy as first-line therapy. Surufatinib, an oral multi-kinase inhibitor targeting VEGFR1-3, FGFR1, and CSF-1R, may enhance chemotherapy efficacy. We evaluated surufatinib combined with doublet (FOLFOX/FOLFIRI) versus triplet (FOLFOXIRI) chemotherapy as second-line treatment for mCRC.

PATIENTS AND METHODS:

This multicentre, open-label, randomized phase-II trial used Simon's minimax two-stage design. Eligible patients had mCRC progressing on or within 6 months after first-line doublet chemotherapy. Patients were randomized 1:1 to surufatinib 250 mg once daily plus either mFOLFOX6/FOLFIRI (doublet cohort, selected based on prior regimen) or FOLFOXIRI (triplet cohort). The primary endpoint was objective response rate (ORR).

RESULTS:

From September 2021 to November 2023, 57 patients were randomized (28 per cohort after one withdrawal). In the doublet cohort, ORR was 35.7% (95% CI: 18.6-55.9), median progression-free survival (PFS) was 5.4 months (95% CI: 3.8-7.0), and median overall survival (OS) was 19.0 months (95% CI: 9.2-28.8). In the triplet cohort, ORR was 39.3% (95% CI: 21.5-59.4), median PFS was 5.8 months (95% CI: 3.3-8.2), and median OS was 10.9 months (95% CI: 6.0-15.8). Grade ≥3 treatment-emergent adverse events occurred more frequently in the triplet (71.4%) versus doublet (57.1%) cohort, with higher rates of treatment delays (89.3% versus 72.0%) and discontinuations (25.0% versus 14.3%).

CONCLUSIONS:

Surufatinib plus doublet chemotherapy showed encouraging antitumor activity and acceptable tolerability in second-line mCRC, warranting further evaluation in a larger randomized trial. In contrast, surufatinib plus triplet chemotherapy was associated with increased toxicity, more frequent treatment delays or discontinuations, and shorter overall survival; this combination is not recommended for further investigation in this setting.ClinicalTrials.gov: NCT04734249Date of registration: January 31, 2021.

2026-09-01·Advanced Science

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Article

作者: Dong, Hanguang ; Long, Jiang ; Xu, Ximo ; Qi, Zihao ; Kong, Tingting ; Tian, Qiang ; Hu, Beiyuan ; Zhang, Xiao ; Yang, Yuqin ; Wu, Chuntao ; Qiu, Zhengjun ; Wu, Fei ; Zheng, Yan ; Jin, Tuo

ABSTRACT:

Pancreatic ductal adenocarcinoma (PDAC), a lethal malignancy with a 5‐year survival of 13%, faces limited therapeutic efficacy due to fibrotic barriers that block drug access to the therapeutic site, systemic toxicity of conventional chemotherapy, and an immunosuppressive tumor microenvironment (TME). Therapeutic agents with different functions, including FOLFIRINOX (FFX), surufatinib (SUR), and anti‐PD‐1 (αPD‐1), are co‐administered to tumors in animal models using microneedle (MN) patches to achieve site‐targeted synergistic efficacy. The core–shell MN structure is used, with the outer layer providing rapid FFX delivery and the inner layer providing sustained release of SUR and αPD‐1. Compared with intratumoral drug injection and traditional systemic administration, MN patch‐mediated administration markedly suppresses tumor growth and liver metastasis at lower doses, reduces systemic drug exposure and toxicity, and prolongs intratumoral drug retention. In addition, the MN patch‐mediated intratumoral co‐delivery reshapes the TME by boosting CD8 + T cells infiltration, inhibiting Foxp3 + regulatory T cells, and reducing CD206 + tumor‐associated macrophages infiltration, resulting in downregulation of tumor epithelial‐mesenchymal transition and increased tumor cell apoptosis. In summary, MN patch‐mediated delivery of therapeutic agents provides sufficient intratumoral doses and minimizes systemic toxicity through multiple microchannels, suggesting that MN patch co‐delivery is a promising adjunct for enhancing efficacy against PDAC.

2026-07-01·Therapeutic Advances in Medical Oncology

Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study

Article

作者: Lv, Huifang ; Chen, Jie ; Zhu, Liming ; Zhang, Ning ; Wang, Yu ; Zhang, Lin ; Suo, Aili ; Liang, Yun ; Zhang, Suzhen ; Hao, Jing ; Chi, Yihebali ; Huang, Li ; Wang, Jian ; Bai, Chunmei ; Hu, Weiyu ; Liu, Ying ; Hu, Hanguang ; Long, Jiang ; Wu, Yinying ; Song, Shanai ; Wang, Xiangling

Background::

Well-differentiated Grade 3 neuroendocrine tumors (G3 NETs) represent a heterogeneous entity with limited therapeutic standards. Surufatinib, a small-molecule inhibitor, has shown efficacy in G1/G2 NETs, but its specific role in the G3 subpopulation and optimal patient selection strategies remain to be elucidated.

Objectives::

This study aimed to evaluate the real-world efficacy of surufatinib in G3 NETs and identify the factors that influenced progression-free survival (PFS).

Design::

A national, multicenter, retrospective observational study.

Methods::

We analyzed data from 77 patients with unresectable or metastatic G3 NETs (Ki-67 > 20%) treated with surufatinib across 15 centers in China between January 2021 and April 2024. The reporting of this study conforms to the STROBE statement. The primary endpoint was PFS. A multivariable Cox proportional hazards model was used to explore prognostic factors.

Results::

The median Ki-67 index was 30% (range: 22%−70%), and 49 patients were of pancreatic origin. A total of 11 patients were treatment-naïve, and 27 patients received surufatinib-based combination therapy. The overall median PFS was 9.4 months (95% confidence interval: 8.5–13.0), and the objective response rate (ORR) was 22.1%. Patients with a Ki-67 index ⩽ 30% had longer PFS than the Ki-67 > 30% group (12.6 vs 9.0 months, hazard ratio = 0.270, p = 0.003). Combined treatment showed a numerical trend toward improved ORR (33.3% vs 16.0%, p = 0.08), but did not significantly prolong PFS compared to surufatinib monotherapy (9.7 vs 9.4 months, p = 0.64).

Conclusion::

Surufatinib was a promising therapeutic option for G3 NETs. Prospective, larger-scale cohorts are warranted to confirm the efficacy and address the predictive markers for better patient selection.

576

项与索凡替尼相关的新闻（医药）

2026-10-21

·李歪歪的投研札记

【交割完成公告：利好兑现，冲高低走】2026.10.21港股复盘笔记：和黄医药

一、盘前消息和个人判断（来源：富途） 2026.10.21早晨，笔者通过富途关注到港股和黄医药发布的新公告及其资讯，利好，且昨日美股和黄医药US上涨，美股XBI指数上涨，生物医药板块情绪偏暖。个人认为，可日内择机对和黄医药做T，止盈率1%左右。复盘：判断正确，策略可行。二、本次和黄医药（HCM/00013.HK）新闻完整专业解读1. 核心公告事实本次新闻是9 月 3 日 BD 签约的交割完成公告（Closing），不是新签协议：标的：HMPL-A830，First-in-class 全球首创 KRAS-EGFR ATTC（抗体靶向偶联药物，属于 ADC 大类），KRAS 是公认难成药靶点，双靶偶联差异化极强HUTCHMED 权益范围：大中华区（内地 + 港澳台）权益自留，大中华以外全球开发、商业化独家授权给 GSK 葛兰素史克；GSK 负责海外全部临床、注册、商业化对价结构：首付款 1.1 亿美元；最高里程碑 11.85 亿美元；叠加净销售额分级特许权使用费；交易潜在总额上限 12.95 亿美元（市场简写 13 亿）本次公告含义：法律交割完成，1.1 亿首付款很快到账，现金直接增厚，管线风险部分转移给跨国大药企 GSK，验证该分子全球价值区分两个时间节点： ✅ 9 月 3 日：签约公告（市场第一波炒作，当日和黄医药港股大涨） ✅ 10 月 21 日：交割完成公告（就是今天这条新闻，属于利好的落地兑现节点，属于 “靴子落地”）2. 配套资讯辅助催化美银证券维持买入、目标价 18 美元机构定价背书，美股 HCM 的卖方评级支撑；当前美股收盘 14.74 美元，离目标价仍有空间FRUSICA-2 肾癌临床完成另一条核心管线索凡替尼相关临床数据落地，丰富实体瘤管线证据链ESMO 欧洲肿瘤年会临近（行业 β 催化）大量中国药企 LBA 口头报告，创新药板块情绪面共振，Biotech / 疫苗 ETF 存在板块行情预期国金证券：创新药管线迭代加速卖方一致看多国产出海管线、license-out 逻辑，是板块宏观叙事3. 利好、利空、交易博弈点拆解 ✅ 利好逻辑现金流入：1.1 亿美金无附加条件首付款，直接改善现金流，对 Biotech 减少融资压力非常关键管线价值验证：GSK 是全球头部药企，愿意承接海外权益，证明 HMPL-A830 的 FIC 差异化、临床潜力得到 MNC 专业认可，重塑管线估值风险分摊：海外昂贵的 III 期临床、FDA 申报、海外商业化巨额成本由 GSK 承担；和黄保留中国区收益，国内市场独享估值范式：港股 Biotech 的 License-out（对外授权）是当前市场最认可的兑现路径，相比单纯临床数据，“卖海外权益拿现金 + 里程碑” 更容易给估值溢价 ⚠️ 利空 / 风险点（交易最容易踩坑）预期已经提前计价（最大风险） 9 月 3 日签约的时候，市场已经充分交易这个 13 亿 BD 的利好；今天只是交割，属于落地利好、利好兑现，典型 “买预期、卖事实” 场景里程碑是或有收入：11.85 亿里程碑不是必然拿到，需要过 I/II/III 期、FDA 获批、销售达标，存在临床失败风险分子还处于早期：HMPL-A830 还在 I 期阶段，距离商业化周期很长，属于早期管线授权，不是成熟上市品种资金结构：和黄是港美两地双重上市，美股 HCM、港股 00013 联动，但流动性差异大；美股夜盘小幅 + 1.56%，港股资金情绪可能偏谨慎板块 β：ESMO 是情绪催化，一旦会议数据不及预期，创新药板块容易集体回调4. 当前盘面解读美股 HCM 10.20 收盘：14.74 美元（+3.95%），52 周区间 9.77–16.33 美元，市值 25.72 亿美金，属于中小市值 Biotech，弹性大、波动高港股 00013 换算价：23.02 港元，当日微跌 0.78%，明显弱于美股昨夜涨幅，港股资金对 “交割落地” 反应平淡，已经提前 price in Beta 系数 0.817，相比创新药指数，波动略低；流通盘偏小，容易被消息短期冲击一句话总结本次新闻本质：9 月签约的重磅出海 BD，今天正式交割、首付款即将到账；属于已经炒作过的利好落地，属于事件兑现，不是全新超预期利好；叠加 ESMO 临近的板块情绪催化，是博弈板块 β，而不是单纯个股利好三、港股同类 License-out（大额对外授权）历史案例复盘：公告当日开盘 + 全天走势统一说明：这类 BD 分为两种：【首次签约公告（全新利好）】、【交割完成公告（兑现利好）】；和黄本次属于后者，本次分开标注，方便对照 ps:市场情绪、当时创新药板块周期、估值位置、预期差都会改变结果案例 1：三生制药（01530.HK） 2025-05-20 【首次签约公告】交易：PD-1/VEGF 双抗 SSGJ-707 授权辉瑞，首付款 12.5 亿美元，总潜在 48 亿美元，当年国产出海首付款纪录消息时间：晚间公告，次一日港股开盘开盘走势：高开 + 18%；盘中最高 + 38%；收盘+32.84% 背景：当时创新药板块处于底部反转初期，市场很久没见到 10 亿美金级首付款，预期差极大，无提前泄密核心特征：低预期 + 首付款极高 + 板块底部 = 大涨案例 2：信达生物（01801.HK）2025-10-22【首次签约公告】交易：3 款 ADC 双抗授权武田，首付款 12 亿美金（含 1 亿股权投资），总额上限 114 亿美元开盘走势：高开约 + 12%；开盘后持续回落，全天收涨仅 + 3.7% 原因：市场担忧管线打包出让、核心资产流出；前期板块已经反弹、部分资金提前埋伏，高开兑现特征：天价总额，但资金对 “出让核心早期管线” 有分歧，高开低走案例 3：诺诚健华（09969.HK）2026-09-24【首次签约公告】交易：和礼来大额合作授权，里程碑总额超 30 亿美元开盘走势：高开 2% 左右，随后快速跳水，收盘大跌近 10% 核心原因：公告前股价已经连续上涨、利好提前透支；市场质疑对价偏低、权益出让过多，典型利好出尽案例 4：石药集团（01093.HK）2026-01-31【首次签约公告】交易：大额海外授权，市场称创纪录 BD 开盘走势：高开后迅速跳水，早盘最深跌近 10%，收盘 - 9.82% 逻辑：市场担心把高价值管线低价卖出、损害长期利润，资金用脚投票，利好变利空案例 5：荣昌生物（09995.HK）维迪西妥早年 Seagen 授权（经典 FIC ADC 出海）版本 1（2021 签约）：首付款 2 亿美金，里程碑最高 26 亿美金当日走势：开盘高开 15%+，全天震荡收涨约 10%；是港股 Biotech ADC 出海标杆行情，当时创新药大牛市周期补充：后续交割公告当日走势：高开 1~3%，大部分时间横盘，收盘几乎平盘，和本次和黄场景高度相似 —— 签约大涨，交割无超额收益案例 6：加科思（01167.HK）2025-12-22 KRAS 管线海外授权交易：KRAS 靶点管线对外授权（和本次和黄靶点赛道一致，KRAS），总额 20 亿美金级别开盘：高开 5%（最高价），随后一路下行，收盘暴跌 - 13.58% 关键共性：KRAS 管线属于早期、研发失败风险高，市场对早期分子的里程碑价值打折；利好兑现资金离场案例 7：中国生物制药（01177.HK）2026-03-04，罗伐昔替尼授权赛诺菲【首次签约】交易：FIC JAK/ROCK 抑制剂，首付款 + 里程碑合计 15.3 亿美金开盘：高开 + 7%，盘中冲高后回落，收盘 + 2.9% 特征：大药企、管线成熟度中等，有板块支撑，但埋伏资金兑现，冲高回落四、规律总结（直接用于本次和黄00013.HK开盘博弈）1）两种公告的完全不同行情规律【首次签约公告（9 月 3 日和黄那次）】如果市场没有提前传闻、预期低：容易高开高走，大涨（三生制药模式）如果前期已经涨过、有传闻：高开低走、利好兑现（诺诚健华、加科思）【交割完成公告（本次 10.21，现在这条新闻）】 ✅ 历史统一规律：几乎很难走出大阳线行情一般是：小幅高开 0~3%，随后震荡、冲高回落，收盘大概率涨不动甚至收跌；利好已经在签约日计价，交割只是流程落地，没有新增超预期信息（荣昌、很多 Biotech 交割日都是这个走势）2）决定当日强弱的 3 个关键变量（你盘中要盯）创新药板块 / 恒生医药 ETF 开盘情绪（ESMO 催化能不能带动整体）美股 HCM 昨夜、盘前价格（美股是情绪锚，昨夜已经涨 3.95%）开盘竞价成交额：如果高开但是竞价量很小，就是诱多兑现；放量高开才具备持续性3）本次和黄对照最贴近的对标：加科思 KRAS 管线授权 + 荣昌生物交割日行情同是 KRAS 难成药靶点、早期 FIC 管线、MNC 接盘；签约当天有行情，交割落地日资金兑现为主。五、交易情景推演（港股00013.HK当日开盘情景）情景 A（概率最高）：小幅高开 0.5~2%，冲高一波后回落，全天震荡，收窄涨幅或者翻绿，利好兑现，对应 Biotech 交割公告的历史常态；情景 B（小概率强行情）：ESMO 板块情绪爆发，整个港股创新药集体暴动，资金借这条新闻二次炒作出海主线，放量高开高走；情景 C：平开 / 低开：资金完全不买交割的账，直接走 “卖事实”。港股 Biotech 波动极大、管线临床风险高。六、当日和黄股价走势情况昨收：23.2 开盘：23.38，0.77% 9:33最高价：24，3.44% 最大止盈率：2.65%，超过笔者安全止盈率1% 股价走势判断：正确策略可行性：可行

引进/卖出临床3期疫苗抗体药物偶联物并购

2026-10-19

·ioncology

ESMO Asia 2026｜瞭望前瞻，百余项中国消化道肿瘤研究闪狮城，不止参与，更是主角

点击蓝字关注我们编者按欧洲肿瘤内科学会亚洲年会（ESMO Asia）是亚太地区肿瘤领域极具影响力的多学科学术盛会，聚焦亚洲高发肿瘤特征、区域人群的诊疗差异，同步传递全球前沿肿瘤研究进展，也是展示中国本土肿瘤原创研究成果、促进亚欧肿瘤学界交流的核心国际平台。2026 ESMO Asia定于12月4~6日在新加坡举办。本届大会消化道肿瘤板块亮点纷呈，共有100余项由中国学者牵头/主导的研究成功入选，研究谱系完整覆盖肝癌、胆道肿瘤、胰腺癌、胃癌、食管癌、胃食管肿瘤及结直肠癌等消化道瘤种。本文将系统梳理本次ESMO Asia入选的中国消化道肿瘤相关研究，第一时间速递来自国际舞台的中国原创循证证据，解读前沿发现。肝癌 Poster&ePoster 海报&电子海报摘要号：399eTiP 英文标题：Acarbose Combined with Camrelizumab (Cam) Plus Rivoceranib (Rivo) as First-Line Treatment for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombus (PVTT): A Prospective, Single-Arm, Phase II Clinical Study中文标题：阿卡波糖联合卡瑞利珠单抗（Cam）与阿帕替尼（Rivo）一线治疗伴门静脉癌栓（PVTT）的肝细胞癌（HCC）：一项前瞻性、单臂Ⅱ期临床研究讲者：Tao Han (Shenyang, CN) 摘要号：379eP 英文标题：TKI combined with immunotherapy and interventional therapy for advanced hepatocellular carcinoma with PVTT: a retrospective study中文标题：TKI联合免疫疗法和介入疗法治疗伴有门静脉癌栓的晚期肝细胞癌：一项回顾性研究讲者：Feng Xia (Chongqing, CN) 摘要号：378eP 英文标题：TKI vs Bevacizumab Combined with Immune Checkpoint Inhibitors Plus Interventional Therapy for First-Line Treatment of Advanced HCC with PVTT: A Multi-center Retrospective Study中文标题：TKI对比贝伐珠单抗联合免疫检查点抑制剂及介入治疗用于伴门静脉癌栓晚期肝细胞癌的一线治疗：一项多中心回顾性研究讲者：Changde Guo (Chongqing, CN) 摘要号：377eP 英文标题：Phase II trial of para-toluenesulfonamide (PTS), a novel liquid intratumoral ablative agent, plus TACE in unresectable HCC中文标题：新型瘤内液体消融剂对甲苯磺酰胺（PTS）联合TACE治疗不可切除肝细胞癌的Ⅱ期研究讲者：Tao Hai (Chengdu, CN) 摘要号：376eP 英文标题：Perioperative Adebrelimab Combined With Lenvatinib in Resectable Hepatocellular Carcinoma: A Multicenter Phase II Study中文标题：阿得贝利单抗联合仑伐替尼围手术期治疗可切除肝细胞癌：一项多中心Ⅱ期研究讲者：Guang Tan (Dalian, CN) 摘要号：375eP 英文标题：SERPINE2 Drives Immunotherapy Resistance via Remodeling Tumor Metabolism in Hepatocellular Carcinoma中文标题：SERPINE2通过重塑肝细胞癌的肿瘤代谢驱动免疫治疗耐药性讲者：Wentao Zhao (Hangzhou, CN) 摘要号：374eP 英文标题：GPD1 Restrains AARS1-Dependent Histone Lactylation to Reprogram Glutamine Competition in Hepatocellular Carcinoma中文标题：GPD1抑制AARS1依赖的组蛋白乳酰化，从而重编程肝细胞癌中的谷氨酰胺竞争讲者：Chi Zhang (Hangzhou, CN) 摘要号：373eP 英文标题：The PHPT1–PTPN1–EGFR axis and lenvatinib response in hepatocellular carcinoma中文标题：PHPT1-PTPN1-EGFR信号轴与肝细胞癌仑伐替尼药物应答讲者：Zheng Lei (Hangzhou, CN) 摘要号：371P 英文标题：GMFB Drives Mitochondrial Dysfunction and Promotes MASH Progression via Inhibition of Mitophagy中文标题：GMFB通过抑制线粒体自噬驱动线粒体功能障碍并促进MASH进展讲者：Weilin Wang (Hangzhou, CN) 摘要号：370P 英文标题：First-in-human phase I study of HH-009, an anti-FGF19 monoclonal antibody, in patients with advanced solid tumors中文标题：HH-009（一种抗FGF19单克隆抗体）在晚期实体瘤患者中的首次人体Ⅰ期研究讲者：Jinhui Xue (Guangzhou, CN) 摘要号：332P 英文标题：The activity and safety of icaritin in patients with child pugh ≥8 unresectable hepatocellular carcinoma: A real-world exploratory study中文标题：淫羊藿素用于Child-Pugh评分≥8分的不可切除肝细胞癌患者的疗效与安全性：一项真实世界探索性研究讲者：Dinghu Zhang (Hangzhou, CN) 摘要号：329P 英文标题：Prognostic Value of Binary-CR in Hepatocellular Carcinoma: Post Hoc Analysis of the TALENTACE Study中文标题：二元完全缓解（Binary-CR）在肝细胞癌中的预后价值：TALENTACE研究事后分析讲者：Linan Yin (Harbin, CN) 摘要号：328P 英文标题：Donafenib Combined with HAIC, Icaritin, and Tislelizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): An Open-Label, Single-Arm Exploratory Study中文标题：多纳非尼联合肝动脉灌注化疗、淫羊藿素及替雷利珠单抗一线治疗不可切除肝细胞癌（uHCC）：一项开放标签、单臂探索性研究讲者：Hui Zeng (Hangzhou, CN) 摘要号：327P 英文标题：Comparative Effectiveness and Prognostic Factors of TACE, Targeted‑Immunotherapy, and Their Combination in Hepatocellular Carcinoma Beyond the Up‑to‑7 Criteria: An IPTW‑Adjusted Retrospective Analysis中文标题：经动脉化疗栓塞术（TACE）、靶向免疫疗法及其联合治疗在超出UPTO-7标准的肝细胞癌中的疗效比较及预后因素：一项基于逆概率加权（IPTW）调整的回顾性分析讲者：Xuwei Guo (Shijiazhuang, CN) 摘要号：326P 英文标题：Conversion outcomes following Yttrium-90 radioembolization-based multidisciplinary treatment for hepatocellular carcinoma: a real-world single-center study中文标题：钇-90放射性栓塞治疗肝细胞癌的多学科综合治疗后的转化结果：一项真实世界单中心研究讲者：JUN FU (Fuzhou, CN) 摘要号：323P 英文标题：Transarterial chemoembolisation plus adebrelimab and apatinib for intermediate-to-advanced hepatocellular carcinoma: a multicentre phase II study中文标题：经动脉化疗栓塞联合阿得贝利单抗与阿帕替尼治疗中晚期肝细胞癌：一项多中心Ⅱ期研究讲者：Junming Xu (Zhangzhou, CN) 摘要号：322P 英文标题：Deferred Immunotherapy Following Induction Arterial Chemotherapy for High-risk Unresectable Hepatocellular Carcinoma: A Biomarker-Guided Strategy from a Long-Term Real-World Cohort中文标题：高危不可切除肝细胞癌诱导动脉化疗后延迟免疫治疗：基于长期真实世界队列的生物标志物指导策略讲者：Ming Zhao (Guangzhou, CN) 摘要号：321P 英文标题：Developing a prognostic score for unresectable hepatocellular carcinoma (uHCC) treated with on-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab (TACE+atezo+bev): a post hoc analysis of the TALENTACE trial中文标题：构建按需经动脉化疗栓塞联合阿替利珠单抗+贝伐珠单抗（TACE+atezo+bev）治疗不可切除肝细胞癌（uHCC）的预后评分模型：TALENTACE研究的事后分析讲者：Yonghong Zhang (Beijing, CN) 摘要号：320P 英文标题：FOLFOX-based HAIC plus lenvatinib and cadonilimab for conversion of unresectable hepatocellular carcinoma (HCC): The phase II CCGLC-011 trial中文标题：基于FOLFOX方案的肝动脉灌注化疗联合仑伐替尼与卡度尼利单抗用于不可切除肝细胞癌的转化治疗：Ⅱ期CCGLC-011研究讲者：Han Gao (Wuhan, CN) 摘要号：315P 英文标题：Real-world Adjuvant Treatment Patterns in Chinese Patients with Hepatocellular Carcinoma Following Curative Surgery or Ablation: A Nationwide Physician Survey中文标题：中国肝细胞癌患者根治性手术或消融术后辅助治疗模式的真实世界研究：一项全国性医生调查讲者：Shengyu Huang (Shanghai, CN) 摘要号：314P 英文标题：Neoadjuvant Lenvatinib, Tislelizumab and Hepatic Arterial Infusion Chemotherapy Followed by Adjuvant Tislelizumab for High-Risk Resectable Hepatocellular Carcinoma: A Phase II Trial中文标题：仑伐替尼联合替雷利珠单抗与肝动脉灌注化疗新辅助治疗，序贯替雷利珠单抗辅助治疗高危可切除肝细胞癌：一项Ⅱ期研究讲者：Weihang Lin (Wenzhou, CN) 摘要号：312P 英文标题：Perioperative finotonlimab plus bevacizumab in resectable hepatocellular carcinoma at high risk of recurrence: A prospective, multicenter, single-arm study中文标题：围手术期菲诺利单抗联合贝伐珠单抗治疗复发高风险可切除肝细胞癌：一项前瞻性、多中心、单臂研究讲者：Zhi-Yong Huang (Wuhan, CN) 摘要号：310P 英文标题：M2 macrophage-derived galectin-9 promotes hepatocellular carcinoma progression by enhancing SLC1A5 membrane stability and glutamine metabolismal中文标题：M2巨噬细胞来源的半乳糖凝集素-9通过增强SLC1A5膜稳定性及谷氨酰胺代谢促进肝细胞癌进展讲者：Yujing Guo (Xi'an, CN) 摘要号：309P 英文标题：Dual MET/AXL Inhibition Suppresses Hepatocellular Carcinoma through Tumour Cell–Intrinsic and Microenvironment-Dependent Mechanisms中文标题：MET/AXL双重抑制通过肿瘤细胞内在机制和微环境依赖性机制抑制肝细胞癌讲者：Chenjing Zhu (Nanjing, CN) 摘要号：308P 英文标题：177Lu-KBD881: A Potent and Selective GPC3-Targeting Radiopharmaceutical Drug Conjugate (RDC) for the Treatment of Hepatocellular Carcinoma中文标题：177Lu-KBD881：一种高效且选择性的GPC3靶向放射性药物偶联物（RDC），用于治疗肝细胞癌讲者：Hongzhu Chu (Chengdu, CN) 摘要号：307P 英文标题：The KCNN4-SLC3A2 Axis and Ferroptosis in the Modulation of Lenvatinib Responsiveness in Hepatocellular Carcinoma中文标题：KCNN4-SLC3A2与铁死亡调控肝细胞癌对仑伐替尼的药物应答讲者：Jun Ran Chen (Hangzhou, CN) 摘要号：306P 英文标题：TRAPPC4-Targeting Biomimetic Nanoparticles Restore MHC Class I Antigen Presentation, Reverse Immune Evasion, and Sensitize Hepatocellular Carcinoma to Anti-PD-1 Therapy中文标题：靶向TRAPPC4的仿生纳米颗粒可恢复MHC Ⅰ类抗原呈递，逆转免疫逃逸，并增强肝细胞癌对PD-1抑制剂的敏感性讲者：Sha Yin (Xi'an, CN) 摘要号：305P 英文标题：Association of tertiary lymphoid structure localization and density with prognosis in hepatocellular carcinoma中文标题：三级淋巴结构定位和密度与肝细胞癌预后的关系讲者：Lei-po Lin (Nanning, CN) 摘要号：301P 英文标题：A phospholipid metabolism-based risk signature identifies PCYT1A as a functional regulator of hepatocellular carcinoma progression中文标题：基于磷脂代谢的风险特征表明，PCYT1A是肝细胞癌进展的功能性调节因子讲者：Nan Hu (Beijing, CN) 摘要号：296P 英文标题：Pretreatment emotional distress and immune checkpoint inhibitor efficacy in hepatocellular carcinoma: the SOLACE prospective cohort study中文标题：肝细胞癌患者治疗前情绪困扰与免疫检查点抑制剂疗效的关系：SOLACE前瞻性队列研究讲者：Lin Ye (Guilin, CN) 胆道肿瘤 Poster&ePoster 海报&电子海报摘要号：388eP 英文标题：First-line dual HER2-targeted therapy plus chemotherapy for patients with HER2-expressing advanced biliary tract cancer: Preliminary results from a prospective study中文标题：一线双重HER2靶向治疗联合化疗治疗HER2表达阳性的晚期胆道癌患者：一项前瞻性研究的初步结果讲者：Yang Ge (Beijing, CN) 摘要号：387eP 英文标题：Prospective multicenter study of first-line inetetamab-based combination therapy for HER2-positive advanced biliary tract cancer中文标题：一项前瞻性多中心研究，评估以伊尼妥单抗为基础的一线联合疗法治疗HER2阳性晚期胆道癌的疗效讲者：Feng Xie (Shenghai, CN) 摘要号：383eP 英文标题：A retrospective study on application of biliary stents in adult liver transplantation中文标题：成人肝移植中胆道支架应用的回顾性研究讲者：Zhongquan Sun (Hangzhou, CN) 摘要号：382eP 英文标题：Selection of Postoperative Adjuvant Therapy Regimens and Efficacy Assessment in Intrahepatic Cholangiocarcinoma中文标题：肝内胆管癌术后辅助治疗方案的选择及疗效评估讲者：Yang Huang (Hangzhou, CN) 摘要号：369P 英文标题：Establishing a Pan-Asia Biliary Tract Cancer Virtual MDT Network: Insights on gaps, priorities, and regional roadmap中文标题：建立泛亚洲胆道癌虚拟多学科团队网络：关于差距、优先事项和区域路线图的见解讲者：Shukui Qin (Nanjing, CN) 摘要号：368P 英文标题：Reducing Regional Disparities in Hepatobiliary Cancer Care Through a Virtual MDT: A Real-World Case from Fuyang, China中文标题：通过虚拟多学科团队减少肝胆肿瘤诊疗中的区域差异：来自中国阜阳的真实案例讲者：Lian-Xin Liu (Hefei, CN) 摘要号：366P 英文标题：Post-acute COVID Monitoring and Timing Assessment of Surgery in Chinese Patients with Hepatobiliary Malignancies and SARS-CoV-2 Infection: A Prospective Observational Study中文标题：中国肝胆恶性肿瘤合并SARS-CoV-2感染患者COVID-19急性期后监测及手术时机评估：一项前瞻性观察研究讲者：Changcheng Tao (Beijing, CN) 摘要号：362P 英文标题：Mapping the nerve-tumour frontier in gallbladder cancer by spatial multi-omics中文标题：利用空间多组学方法绘制胆囊癌神经肿瘤边界图谱讲者：Huisi He (Shanghai, CN) 摘要号：361P 英文标题：Efficacy and Conversion Potential of Gemcitabine-Cisplatin Combined with Immunotherapy and Targeted Therapy in Advanced Biliary Tract Cancer: A Real-World Study中文标题：吉西他滨-顺铂联合免疫疗法和靶向疗法治疗晚期胆道癌的疗效和转化潜力：一项真实世界研究讲者：Lang Chen (Chengdu, CN) 摘要号：360P 英文标题：OLFM4, FGFR1 signalling and neutrophil remodelling in biliary tract cancer中文标题：OLFM4、FGFR1信号通路和中性粒细胞重塑在胆道癌中的作用讲者：Huisi He (Shanghai, CN) 摘要号：357P 英文标题：Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and pucotenlimab for conversion of initially unresectable intrahepatic cholangiocarcinoma (iCCA): The phase II CCGLC-013 trial中文标题：肝动脉灌注化疗（HAIC）联合仑伐替尼与普特利单抗用于初始不可切除肝内胆管癌（iCCA）的转化治疗：Ⅱ期CCGLC-013研究讲者：Han Gao (Wuhan, CN) 摘要号：353P 英文标题：Composite Biomarker Profiling Identifies Large Duct Type Intrahepatic Cholangiocarcinoma as a Chemotherapy-Responsive Subtype中文标题：复合生物标志物分析鉴定出大导管型肝内胆管癌为化疗敏感亚型讲者：Zhuo Li (Beijing, CN) 摘要号：352P 英文标题：A CXCL10+ Macrophage-Centred Spatial Immune Niche Is Associated With Response to Camrelizumab Plus GEMOX in Unresectable Gallbladder Cancer中文标题：以CXCL10⁺巨噬细胞为核心的空间免疫微环境生态位与不可切除胆囊癌患者卡瑞利珠单抗联合GEMOX方案的治疗应答相关讲者：Wanying Deng (Guangzhou, CN) 摘要号：348P 英文标题：Peripheral nerve infiltration affects the efficacy of neoadjuvant immunotherapy for intrahepatic cholangiocarcinoma中文标题：周围神经浸润影响肝内胆管癌新辅助免疫疗法的疗效讲者：Shu Lizhuang (Shanghai, CN) 摘要号：347P 英文标题：Durvalumab/Pembrolizumab plus Gemcitabine, Cisplatin, and Surufatinib for Advanced Biliary Tract Cancer: A Phase 2 Study中文标题：度伐利尤单抗/帕博利珠单抗联合吉西他滨、顺铂与索凡替尼治疗晚期胆道恶性肿瘤：一项Ⅱ期研究讲者：Miaomiao Gou (Beijing, CN) 摘要号：345P 英文标题：Gemcitabine-based chemotherapy plus PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors for initially unresectable intrahepatic cholangiocarcinoma: A multicenter, retrospective cohort study中文标题：吉西他滨为基础的化疗联合PD-1/PD-L1抑制剂及酪氨酸激酶抑制剂治疗初始不可切除肝内胆管癌：一项多中心回顾性队列研究讲者：Yuan Ding (Hangzhou, CN) 胰腺癌 Poster&ePoster 海报&电子海报摘要号：396eP 英文标题：Efficacy and safety of splenic artery infusion chemotherapy versus systemic chemotherapy in advanced pancreatic body/tail cancer: a real-world study中文标题：脾动脉灌注化疗与全身化疗治疗晚期胰体尾癌的疗效和安全性：一项真实世界研究讲者：Jianfeng Huang (Guangzhou, CN) 摘要号：343P 英文标题：Efficacy and safety of chemoimmunotherapy in advanced pancreatic cancer中文标题：化疗免疫疗法治疗晚期胰腺癌的疗效和安全性讲者：Hanqi Yu (Hangzhou, CN) 摘要号：342P 英文标题：Personalized mRNA Cancer Vaccine in Pancreatic Cancer: Feasibility, Safety, and Preliminary Biomarker Signals from Real-World Data中文标题：胰腺癌个性化mRNA癌症疫苗：可行性、安全性及来自真实世界数据的初步生物标志物信号讲者：Mantang Qiu (Beijing, CN) 摘要号：341P 英文标题：Neoadjuvant PD-1 Blockade (Toripalimab) Combined with Gemcitabine and Nab-Paclitaxel for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Prospective Interventional Study中文标题：新辅助PD-1阻断（特瑞普利单抗）联合吉西他滨和白蛋白紫杉醇治疗临界可切除和局部晚期胰腺癌：一项前瞻性干预研究讲者：Ziheng Guo (Chengdu, CN) 摘要号：340P 英文标题：Fruquintinib monotherapy as third-line or later treatment for advanced pancreatic ductal adenocarcinoma: Updated results from a multicenter phase II study中文标题：呋喹替尼单药用于晚期胰腺导管腺癌三线及以上治疗：一项多中心Ⅱ期研究更新结果讲者：Jieyun Zhang (Shanghai, CN) 摘要号：338P 英文标题：Synthetic Lethality Targeting IL-1β in KRAS-Mutant Cancer中文标题：针对KRAS突变癌症中IL-1β的合成致死性讲者：Yukai Shan (Hangzhou, CN) 胃癌 Rapid Oral session 快速口头报告摘要号：1044RO 英文标题：Personalized MRD Monitoring Predicts Recurrence and Guides Tailored Adjuvant Therapy in Post-Neoadjuvant Locally Advanced Gastric Cancer: A Prospective, Multicenter Cohort Study中文标题：个体化MRD监测预测新辅助治疗后局部晚期胃癌复发并指导个体化辅助治疗：一项前瞻性、多中心队列研究讲者：李子禹（北京大学肿瘤医院） Poster&ePoster 海报&电子海报摘要号：YO30 英文标题：Gastric hepatoid adenocarcinoma achieving pathological complete response after conversion therapy with chemotherapy, trastuzumab, and cadonilimab: a case report中文标题：一例胃肝样腺癌经化疗、曲妥珠单抗和卡度尼利单抗转化治疗后达到病理完全缓解的病例报告讲者：Yarong Li (Taiyuan, CN) 摘要号：1092eP 英文标题：Irinotecan liposome combined with albumin-bound paclitaxel in second-line therapy of advanced gastric cancer: A Single-Arm, Single-Center Clinical Study中文标题：伊立替康脂质体联合白蛋白结合型紫杉醇二线治疗晚期胃癌：一项单臂、单中心临床研究讲者：Rongrong Li (Changsha, CN) 摘要号：1089eP 英文标题：Association between the age-adjusted Charlson Comorbidity Index and postoperative survival in patients with gastric cancer中文标题：年龄校正查尔森合并症指数与胃癌患者术后生存的相关性研究讲者：Yulan Lin (Fuzhou, CN) 摘要号：1086eP 英文标题：Immune-Stromal Characterization of HER2/PD-L1-Defined Subtypes in Gastric Cancer中文标题：胃癌中HER2/PD-L1定义亚型的免疫基质特征分析讲者：Ming-Huang Chen (Taipei City, TW) 摘要号：1076P 英文标题：Multi-Task Deep Learning for Endoscopic Differentiation of Type 1 Grade 1/2 Gastric Neuroendocrine Tumors, Gastric Polyps, and Gastrointestinal Stromal Tumors中文标题：基于多任务深度学习的内镜鉴别诊断：Ⅰ型1/2级胃神经内分泌肿瘤、胃息肉和胃肠道间质瘤讲者：Jiaojiao Hou (Shijiazhuang, CN) 摘要号：1072P 英文标题：Envafolimab Combined with XELOX or SOX as Adjuvant Therapy for Locally Advanced Gastric Cancer: A Prospective, Single-Arm, Exploratory Study中文标题：Envafolimab联合XELOX或SOX方案辅助治疗局部晚期胃癌：一项前瞻性、单臂、探索性研究讲者：Danyu Ma (Wuxi, CN) 摘要号：1055P 英文标题：Peripheral CD8+ T Cell Senescence and Lymphocyte Reduction Emerge at Premalignant Gastric Stages中文标题：外周CD8+ T细胞衰老和淋巴细胞减少出现在胃癌前期阶段讲者：Da-cen Lin (Fuzhou, CN) 摘要号：1054P 英文标题：Single-cell profiling of gastric mucosal remodeling in zolbetuximab-induced gastritis 中文标题：佐妥昔单抗诱导胃炎中胃黏膜重塑的单细胞图谱分析讲者：Miaomiao Gou (Beijing, CN) 摘要号：1053P 英文标题：Baseline clinicogenomic modeling of response groups in gastric cancer treated with immunochemotherapy中文标题：免疫化疗治疗胃癌患者反应组的基线临床基因组学模型讲者：Xin Han (Shijiazhuang, CN) 摘要号：1052P 英文标题：Correlation between Dynamic Changes in Natural Killer Cell Activity, Nutritional Status and Therapeutic Efficacy in Patients with Advanced Gastric Cancer中文标题：晚期胃癌患者自然杀伤细胞活性动态变化、营养状况与治疗效果的相关性研究讲者：Dan Wu (Hefei, CN) 摘要号：1051P 英文标题：The Impact of Delayed Diagnosis and Treatment on Self-Reported Quality of Life in Gastric Cancer Patients: A Prospective Cohort Study中文标题：延迟诊断和治疗对胃癌患者自述生活质量的影响：一项前瞻性队列研究讲者：Xinyu Chen (Fuzhou, CN) 食管癌 Proffered Paper session 优选论文专场摘要号：1043O 英文标题：Primary Results of Risvutatug Rezetecan (Ris-Rez) in Patients with Advanced Esophageal Squamous-Cell Carcinoma (ESCC): A Phase 2 Clinical Trial中文标题：Risvutatug Rezetecan（Ris-Rez）治疗晚期食管鳞状细胞癌（ESCC）患者的初步结果：一项Ⅱ期临床试验讲者：李宁（河南省肿瘤医院） Poster&ePoster 海报&电子海报摘要号：1065P 英文标题：Camrelizumab plus paclitaxel and nedaplatin conversion therapy in ESCC: A single-arm phase II trial with retrospective biomarker analysis of combined CUL4A and HSP90β for survival prediction中文标题：卡瑞利珠单抗联合紫杉醇和奈达铂治疗ESCC：一项单臂Ⅱ期临床试验，回顾性分析CUL4A和HSP90β联合生物标志物对生存预测的价值讲者：Jinhong Zhu (Harbin, CN) 摘要号：1064P 英文标题：The Efficacy and Safety of Cetuximab β plus Tislelizumab and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CTC-LAESCC): single-arm, phase II study中文标题：西妥昔单抗β联合替雷利珠单抗及放化疗治疗局部晚期食管鳞癌：CTC-LAESCC单臂Ⅱ期研究讲者：Xiuyong Liao (Chongqing, CN) 摘要号：1063P 英文标题：Adebrelimab plus albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter, single-arm, phase II study中文标题：阿得贝利单抗联合白蛋白紫杉醇与奈达铂用于可切除局部晚期食管鳞癌的新辅助治疗：一项多中心、单臂Ⅱ期研究讲者：Jianqun Ma (Harbin, CN) 摘要号：1060P 英文标题：Survival Outcomes and Ultrasound Radiomics Prognostication in Cervical Lymph Node Oligometastasis Post-Esophagectomy: A Multicenter Retrospective Study Comparing Surgical and Non-Surgical Approaches中文标题：食管切除术后颈部淋巴结寡转移的生存结局与超声组学预后预测：一项对比手术与非手术治疗方案的多中心回顾性研究讲者：Junying Chen (Guangzhou, CN) 摘要号：1059P 英文标题：Preliminary results for a phase II study of sintilimab combined with chemotherapy followed by concurrent chemoradiotherapy as conversion therapy for unresectable locally advanced esophageal squamous cell carcinoma (NICE-CS trial)中文标题：信迪利单抗联合化疗序贯同步放化疗作为不可切除局部晚期食管鳞癌转化治疗的Ⅱ期研究初步结果（NICE-CS研究）讲者：Yuxi Yi (Shanghai, CN) 摘要号：1058P 英文标题：Anlotinib plus Toripalimab with Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II Trial中文标题：安罗替尼联合特瑞普利单抗序贯新辅助放化疗治疗局部晚期食管鳞癌：一项Ⅱ期临床试验讲者：Qiwei Yao (Fuzhou, CN) 摘要号：1056P 英文标题：Development and validation of a clinical decision score to guide adjuvant therapy in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy中文标题：开发和验证临床决策评分，以指导新辅助免疫化疗后食管鳞状细胞癌的辅助治疗讲者：Haiping Jiang (Hangzhou, CN) 摘要号：1049P 英文标题：A Multicenter, Real-world Study on Impact of Smoking on Clinical Outcomes and the Tumor Immune Microenvironment in Metastatic ESCC Patients Receiving First-Line PD-1 Inhibitors: A Role for CD8+ TIL Infiltration中文标题：一项多中心、真实世界研究评估吸烟对接受一线PD-1抑制剂治疗的转移性食管鳞状细胞癌（ESCC）患者的临床结局和肿瘤免疫微环境的影响：CD8+肿瘤浸润淋巴细胞浸润的作用讲者：Fan Dong (Guangzhou, CN) 胃食管肿瘤 Poster&ePoster 海报&电子海报摘要号：1096P 英文标题：Fruquintinib combined with cadonilimab and nab-paclitaxel as second‑line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)中文标题：呋喹替尼联合卡度尼利单抗和白蛋白紫杉醇作为晚期胃或胃食管交界处腺癌（GC/GEJC）的二线治疗讲者：Jieyun Zhang (Shanghai, CN) 摘要号：1068P 英文标题：Long-term survival follow-up of camrelizumab plus Nab-POF conversion therapy in initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-GC001中文标题：卡瑞利珠单抗联合Nab-POF转化疗法治疗初始不可切除的局部晚期或局限性转移性胃癌或胃食管交界处腺癌的长期生存随访：FDZL-GC001讲者：Wanjing Feng (Shanghai, CN) 摘要号：1067P 英文标题：Biomarker-Driven Assessment of Immunochemotherapy with or without Fruquintinib as First-Line Treatment for Advanced Gastric/GEJ Adenocarcinoma: Initial Clinical Results and Subgroup Analysis from the MGC-FLORA Study中文标题：基于生物标志物的免疫化疗联合或不联合呋喹替尼作为晚期胃/GEJ腺癌一线治疗的评估：MGC-FLORA研究的初步临床结果和亚组分析讲者：Chenchen Wang (Shanghai, CN) 摘要号：1066P 英文标题：HCB101 with ramucirumab and paclitaxel as a CD47–SIRPα innate immune combination strategy in previously treated advanced gastric/GEJ cancer中文标题：HCB101联合雷莫芦单抗和紫杉醇作为CD47-SIRPα先天免疫联合策略，用于治疗既往接受过治疗的晚期胃/GEJ癌讲者：Fangling Ning (Yantai, CN) 结直肠癌 Proffered Paper session 优选论文专场摘要号：152O 英文标题：Regorafenib Combined with Trifluridine/Tipiracil versus Regorafenib Monotherapy in Refractory Metastatic Colorectal Cancer (FDZL-REGOT): A Randomized Phase II Trial中文标题：瑞戈非尼联合曲氟尿苷/替匹嘧啶对比瑞戈非尼单药治疗难治性转移性结直肠癌（FDZL-REGOT）：一项随机Ⅱ期试验讲者：李文桦（复旦大学附属肿瘤医院） Rapid Oral session 快速口头报告摘要号：154RO 英文标题：Amivantamab monotherapy or in combination with chemotherapy in RAS/BRAF wildtype metastatic colorectal cancer: Asian subset analysis from the phase 1b/2 OrigAMI-1 study中文标题：埃万妥单抗单药或联合化疗治疗RAS/BRAF野生型转移性结直肠癌：Ⅰb/Ⅱ期OrigAMI-1研究的亚洲亚组分析讲者：袁瑛（浙江大学医学院附属第二医院）摘要号：155RO 英文标题：Single-cell transcriptomic atlas reveals myeloid reprogramming and persistent clonal T-cell expansion underlying pathological complete response to split-course hypofractionated chemoradioimmunotherapy in pMMR/MSS locally advanced rectal cancer中文标题：单细胞转录组图谱揭示pMMR/MSS局部晚期直肠癌分段大分割放化疗联合免疫治疗病理完全缓解的髓系重编程与持续性克隆性T细胞扩增机制讲者：郑榕（福建医科大学附属协和医院）摘要号：1046RO 英文标题：SYS6010 combined with SYH2051 in advanced solid tumors: results from a phase Ib中文标题：SYS6010联合SYH2051治疗晚期实体瘤：一项Ⅰb期研究结果讲者：林榕波（福建省肿瘤医院）摘要号：1047RO 英文标题：Safety and feasibility of CLDN18.2-specific CAR-NK cells in advanced gastrointestinal cancers: A phase 1 trial中文标题：CLDN18.2特异性CAR-NK细胞治疗晚期消化道肿瘤的安全性与可行性：一项Ⅰ期试验讲者：杨柳（浙江省人民医院） Poster&ePoster 海报&电子海报摘要号：235eP 英文标题：Oxaliplatin-associated affective toxicity in colorectal cancer is mediated by the IDO1-kynurenine-gut microbiota-ACC neuroimmune axis中文标题：IDO1-犬尿氨酸-肠道菌群-前扣带回皮层神经免疫轴介导结直肠癌中奥沙利铂相关情感毒性讲者：Zhijun Mao (Xian, CN) 摘要号：234eP 英文标题：Trajectories and risk stratification of patient-reported affective toxicity during colorectal cancer chemotherapy: a real-world longitudinal study中文标题：结直肠癌化疗期间患者报告的情感毒性轨迹和风险分层：一项真实世界纵向研究讲者：Yuming Zhang (Xi'an, CN) 摘要号：226eP 英文标题：KBD166: A Novel Neurotensin Receptor 1 (NTSR1) Ligand for Solid Tumor Therapy中文标题：KBD166：用于实体瘤治疗的新型神经降压素受体1（NTSR1）配体讲者：Jing Zhang (Chengdu, CN) 摘要号：224eP 英文标题：Vitamin E plus fruquintinib and tislelizumab in refractory microsatellite-stable metastatic colorectal cancer: interim results of the phase II VENTIF study中文标题：维生素E联合呋喹替尼与替雷利珠单抗治疗难治性微卫星稳定转移性结直肠癌：Ⅱ期VENTIF研究中期结果讲者：Dawei Li (Shanghai, CN) 摘要号：218eP 英文标题： Safety and Feasibility of Preserving the Left Colic Artery and Clearing No.253 Lymph Nodes via Caudal Triangular Region Dissection in LRRRC for Rectal Cancer中文标题：低位局部进展期直肠癌经尾侧三角区清扫保留左结肠动脉并清扫253组淋巴结的安全性与可行性讲者：Pengxing Li (Nanping, CN) 摘要号：201P 英文标题：Fruquintinib Monotherapy Versus Fruquintinib Combined with Chemotherapy in Patients with Refractory Metastatic Colorectal Cancer: A Real-World Retrospective Cohort Study中文标题：呋喹替尼单药对比呋喹替尼联合化疗用于难治性转移性结直肠癌患者：一项真实世界回顾性队列研究讲者：Jen Pei Huang (Taipei City, TW) 摘要号：198P 英文标题：Propensity Score Matching Multicenter Study of Maintenance Strategies versus Drug-free Treatment Break After First-line Systemic Therapy for Metastatic Colorectal Cancer - The Retrospective TRACC Registry中文标题：转移性结直肠癌一线系统治疗后维持治疗策略对比停药治疗间歇的疗效：一项基于TRACC回顾性登记库的多中心倾向性评分匹配研究讲者：Kin Tsun Lee (Hong Kong, HK) 摘要号：197P 英文标题：Antibiotic Exposure Prior to Radiotherapy and Survival Outcomes in Colorectal Cancer: A Propensity Score-Matched Real-World Analysis Using the TriNetX Global Network中文标题：结直肠癌患者放疗前抗生素暴露与生存结局：基于TriNetX全球数据库的倾向性评分匹配真实世界分析讲者：Tisha Lazuana (Taipei City, TW) 摘要号：195P 英文标题：BETTER Trial: The Efficacy and Safety of Bevacizumab Combined with Trifluridine/Tipiracil, Stereotactic Body Radiotherapy, and Tislelizumab in Patients with Microsatellite-Stable Metastatic Colorectal Cancer Receiving Third-Line Therapy中文标题：BETTER研究：贝伐珠单抗联合曲氟尿苷替匹嘧啶、立体定向体部放疗及替雷利珠单抗三线治疗微卫星稳定转移性结直肠癌的疗效与安全性讲者：Qun Zhang (Nanjing, CN) 摘要号：194P 英文标题：UGT1A1 genotype-guided Irinotecan liposome combined with 5-FU/LV+ bevacizumab as first-line therapy in metastatic colorectal cancer：multicenter, phase II clinical study中文标题：基于UGT1A1基因型指导的脂质体伊立替康联合5-FU/LV及贝伐珠单抗一线治疗转移性结直肠癌：一项多中心Ⅱ期临床研究讲者：Yuwen Zhou (Chengdu, CN) 摘要号：193P 英文标题：Precemtabart tocentecan (Precem-TcT) in Chinese patients with metastatic colorectal cancer (mCRC): results from the PROCEADE®-CRC-02 study中文标题：Precemtabart tocentecan (Precem-TcT) 治疗中国转移性结直肠癌 (mCRC) 患者：PROCEADE®-CRC-02研究结果讲者：Yanhong Deng (Guangzhou, CN) 摘要号：192P 英文标题：Sintilimab plus bevacizumab and CapeOx as first-line treatment in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer patients: Updated survival results and biomarker analyses of the BBCAPX-II study中文标题：信迪利单抗联合贝伐珠单抗与CapeOx方案一线治疗RAS突变、微卫星稳定、不可切除转移性结直肠癌：BBCAPX-Ⅱ研究更新生存结果及生物标志物分析讲者：Ning Zhu (Hangzhou, CN) 摘要号：190P 英文标题：Final analysis of CAPability-01: A phase Il trial of combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer中文标题：CAPability-01研究最终分析：抗PD-1联合HDAC抑制剂与抗血管内皮生长因子药物治疗 MSS/pMMR结直肠癌的Ⅱ期研究讲者：Yu-Kun Chen (Guangzhou, CN) 摘要号：188P 英文标题：Metastasectomy, hepatic resection margin status, and survival with first-line panitumumab or cetuximab in RAS wild-type metastatic colorectal cancer: a Taiwanese multicenter cohort中文标题：RAS野生型转移性结直肠癌一线使用帕尼单抗或西妥昔单抗治疗时，转移灶切除术、肝切除切缘状态与生存的相关性：一项中国台湾多中心队列研究讲者：Hung-Chih Hsu (Taoyuan City, TW) 摘要号：186P 英文标题：Postoperative intraperitoneal raltitrexed after cytoreductive surgery for colorectal peritoneal metastases: a single-centre, open-label, phase 1b dose-escalation study中文标题：结直肠癌腹膜转移肿瘤减灭术后行术后腹腔内雷替曲塞给药：一项单中心、开放标签、Ⅰb期剂量递增研究讲者：Guoxiang Cai (Shanghai, CN) 摘要号：184P 英文标题：Peritumoral multimodal radiomics predicts CRLM recurrence中文标题：肿瘤周围多模态放射组学预测CRLM复发讲者：Yanzong Lin (Xiamen, CN) 摘要号：183P 英文标题：Time-Varying Relapse Risk and Surveillance Intensity After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases中文标题：初始无法切除的结直肠癌肝转移患者行转化性肝切除术后，复发风险随时间变化及监测强度讲者：Yijiao Chen (Shanghai, CN) 摘要号：180P 英文标题：CT–MRI Multimodal Imaging-based Characterization of Indeterminate Pulmonary Nodules in Rectal Cancer中文标题：基于CT-MRI多模态成像的直肠癌肺部不确定结节的特征分析讲者：Liao Yijun (Guangzhou, CN) 摘要号：178P 英文标题：Neoadjuvant fruquintinib plus tislelizumab and mCapeOX for pMMR/MSS locally advanced rectal cancer: Safety lead-in results of a prospective, randomized, multicenter trial中文标题：新辅助呋喹替尼联合替雷利珠单抗和mCapeOX方案治疗pMMR/MSS局部晚期直肠癌：一项前瞻性、随机、多中心试验的安全性导入结果讲者：Xiaokang Lei (Beijing, CN) 摘要号：171P 英文标题：Tissue-specific mapping of genetic susceptibility in colorectal cancer identifies epithelial and endothelial driver genes and validates the association between WDR74 and oxaliplatin chemoresistance中文标题：结直肠癌遗传易感性的组织特异性定位鉴定出上皮和内皮驱动基因，并验证了WDR74与奥沙利铂化疗耐药性之间的关联讲者：Tingyao Liu (Zhuhai, CN) 摘要号：168P 英文标题：NAMPT-driven NAD⁺ metabolism orchestrates a tumor stiffness–immune axis that mediates immunotherapy resistance in MSS colorectal cancer中文标题：NAMPT驱动的NAD⁺代谢调控肿瘤硬度-免疫轴，从而介导MSS型结直肠癌的免疫治疗耐药性讲者：Chenyang Ye (Hangzhou, CN) 摘要号：165P 英文标题：Preclinical and first-in-human evaluation of [68Ga]NODAGA-SNA009 for PET imaging of GPA33 expression in colorectal cancer中文标题：[68Ga]NODAGA-SNA009 用于PET成像检测结直肠癌中GPA33表达的临床前和首次人体评估讲者：Dong Dai (Tianjin, CN) 摘要号：164P 英文标题：Attention-enhanced digital pathology for MSI prediction in colorectal cancer中文标题：注意力增强型数字病理学在结直肠癌MSI预测中的应用讲者：Yunxia Huang (Xiamen, CN) 摘要号：156P 英文标题：Smoking promotes colorectal cancer risk mediated by type 2 diabetes: a Mendelian randomization study中文标题：吸烟通过2型糖尿病介导增加结直肠癌风险：一项孟德尔随机化研究讲者：Yu Zhou (Fuzhou, CN) （来源：肿瘤瞭望消化时讯）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期免疫疗法临床结果

2026-10-19

·ioncology

ESMO Asia 2026丨瞭望前瞻，20项中国妇瘤研究闪耀狮城，不止参与，更是主角

编者按 2026年欧洲肿瘤内科学会亚洲年会（ESMO Asia 2026）将于2026年12月4日~6日在新加坡举行，妇科肿瘤领域汇聚了来自亚太地区多个国家和地区的口头报告、快速口头报告与壁报研究成果。本届大会妇瘤专场中，来自中国的专家团队在卵巢癌、子宫内膜癌、宫颈癌及子宫肉瘤、外阴癌等多个瘤种方向均有重要成果入选，覆盖晚期卵巢癌新辅助化疗与间歇性肿瘤细胞减灭术、抗体药物偶联物（ADC）联合免疫治疗、PARP抑制剂与靶向组合新辅助治疗、生物标志物与ctDNA监测、深度学习与影像组学无创预测等多个前沿方向，充分展现了中国妇瘤领域的临床研究与转化创新能力。现将本届大会妇瘤领域由中国专家完成或牵头的摘要按专场分类汇总如下。（由于目前多数研究摘要全文尚未正式发布，本次整理仅基于已公开的标题信息，如有疏漏或表述偏差，敬请留言指正。）一、优选口头报告专场摘要号：468O 英文标题：Systematic lymphadenectomy during interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a multicentre retrospective cohort study in China中文标题：晚期上皮性卵巢癌新辅助化疗后间歇性肿瘤细胞减灭术中系统性淋巴结清扫术：中国多中心回顾性队列研究讲者：Jianye Wang（中国 · 济南）二、快速口头报告专场摘要号：473RO 英文标题：Neoadjuvant Disitamab Vedotin Plus Carboplatin in Advanced Ovarian Cancer: A Multicenter Phase II Trial中文标题：维迪西妥单抗（Disitamab Vedotin）联合卡铂新辅助治疗晚期卵巢癌：多中心II期试验讲者：Wei Wei（中国 · 广州）摘要号：LBA6 英文标题：Effect of sodium thiosulfate on nephrotoxicity in patients receiving cisplatin hyperthermic intraperitoneal chemotherapy (STONE-HIPEC): A multicenter, randomized controlled trial中文标题：硫代硫酸钠对接受顺铂腹腔热灌注化疗患者肾毒性的影响（STONE-HIPEC）：多中心随机对照试验讲者：Jie Lan（中国 · 广州）摘要号：474RO 英文标题：Phase I/II study of WJB001 capsule, a WEE1 inhibitor, in patients with advanced solid tumors中文标题：WEE1抑制剂WJB001胶囊治疗晚期实体瘤患者的I/II期研究讲者：Ning Li（中国 · 北京）摘要号：476RO 英文标题：Bulumtatug Fuvedotin (BFv, 9MW2821) plus Toripalimab with or without Bevacizumab as First-Line Treatment for patients with persistent, recurrent, or metastatic cervical cancer: Updated Results From a Phase Ib/II Clinical Study中文标题：Bulumtatug Fuvedotin（BFv，9MW2821）联合特瑞普利单抗±贝伐珠单抗一线治疗持续性、复发性或转移性宫颈癌：Ib/II期临床研究更新结果讲者：Hanmei Lou（中国 · 杭州）摘要号：LBA7 英文标题：Camrelizumab plus famitinib versus platinum-based chemotherapy with or without bevacizumab as first-line therapy for recurrent or metastatic cervical cancer patients with PD-L1 combined positive score ≥1: Subgroup results from a phase III study中文标题：卡瑞利珠单抗联合法米替尼对比含铂化疗±贝伐珠单抗一线治疗PD-L1联合阳性评分≥1复发性或转移性宫颈癌：III期研究亚组结果讲者：吴小华（复旦大学附属肿瘤医院）三、壁报专场专场信息：2026年12月4日（周五）摘要号：486P 英文标题：An exploratory study of neoadjuvant iparomlimab and tuvonralimab (QL1706) plus chemotherapy in locally advanced cervical cancer中文标题：艾帕洛利托沃瑞利单抗（QL1706）加化疗新辅助治疗局部晚期宫颈癌的探索性研究讲者：Jing Zhu（中国 · 合肥）摘要号：494P 英文标题：Bicenter Noninvasive Identification of p53abn EC by Integrating MRI-Derived Spatial Microenvironmental Features中文标题：整合MRI空间微环境特征无创识别p53突变型子宫内膜癌的双中心研究讲者：Huijie Dai（中国 · 济南）摘要号：496P 英文标题：Structured Case Summaries and Guardrails for Endometrial Cancer Adjuvant Decisions中文标题：子宫内膜癌辅助治疗决策的结构化病例摘要与防护准则讲者：Kuan-chen Lu（中国台湾 · 台北）摘要号：503P 英文标题：Non-invasive Prediction of BRCA Mutation Status in Ovarian Cancer Using Whole-body Tumor Burden Deep Learning: A Novel Pathway Towards Precision Medicine and Accessible Genetic Testing中文标题：基于全身肿瘤负荷深度学习无创预测卵巢癌BRCA突变状态：迈向精准医疗与可及性基因检测的新途径讲者：Xinru Li（中国 · 上海）摘要号：507P 英文标题：Pamiparib Plus Surufatinib as Neoadjuvant Treatment for Advanced Unresectable Ovarian Cancer (PASSION): A Prospective, Single-Arm, Phase 2 Trial中文标题：帕米帕利联合索凡替尼新辅助治疗晚期不可切除卵巢癌（PASSION）：前瞻性单臂II期试验讲者：Wei Xiong（中国 · 合肥）摘要号：519P 英文标题：Chemotherapy, survival and recurrence in FIGO stage I undifferentiated uterine sarcoma and high-grade endometrial stromal sarcoma: a dual-cohort study中文标题：FIGO I期未分化子宫肉瘤与高级别子宫内膜间质肉瘤的化疗、生存与复发：双队列研究讲者：Xinyu Zhang（中国 · 福州）摘要号：520P 英文标题：Risk Factors for Disease Progression and Survival Impact of Post-Progression Surgery in Uterine Sarcoma: A Retrospective Cohort Study中文标题：子宫肉瘤疾病进展危险因素及进展后手术对生存的影响：回顾性队列研究讲者：Xiaoting Huang（中国 · 福州）摘要号：521P 英文标题：Risk Stratification for Optimizing Treatment Decisions in Vulvar Squamous Cell Carcinoma: A Multicenter Study Based on Recursive Partitioning Analysis中文标题：基于递归分割分析优化外阴鳞状细胞癌治疗决策的多中心风险分层：一项多中心研究讲者：Yuqin Wang（中国 · 福州）摘要号：528TiP 英文标题：Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer中文标题：化疗联合盐酸普萘洛尔作为晚期高级别浆液性卵巢癌新辅助治疗讲者：Bairong Xia（中国 · 合肥）摘要号：536eP 英文标题：Postoperative ctDNA Assessment in Endometrial Cancer Beyond Integrated Genomic Risk Models, Reshaping Precision Decisions for Adjuvant Therapy中文标题：子宫内膜癌术后ctDNA评估超越整合基因组风险模型，重塑辅助治疗精准决策讲者：Yanzi Chen（中国 · 贵阳）摘要号：541eP 英文标题：GLT8D2-mediated PD-L1 N-glycosylation promotes tumor immune evasion in ovarian cancer peritoneal metastasis中文标题：GLT8D2介导的PD-L1 N-糖基化促进卵巢癌腹膜转移的肿瘤免疫逃逸讲者：Yinyin Xu（中国 · 广州）摘要号：522P 英文标题：Pan-Gynecologic Assessment of HER2 Expression and Clinicopathologic Features in a Large Retrospective Cohort Using ASCO/CAP Gastric Cancer Criteria (HERGYN Study)中文标题：HERGYN研究：采用ASCO/CAP胃癌标准对大型回顾性队列进行泛妇科肿瘤HER2表达与临床病理特征评估讲者：Peng-Hui Wang（中国台湾 · 台北）摘要号：543eP 英文标题：Single-cell screening of PARP inhibitor-induced malignant epithelial programs identifies an immune-visible prognostic axis in high-grade serous ovarian cancer中文标题：PARP抑制剂诱导的恶性上皮程序的单细胞筛选鉴定出高级别浆液性卵巢癌免疫可见的预后轴讲者：He Zhang（中国 · 北京）摘要号：549eP 英文标题：Molecular-Directed Therapy Utilizing Multi-Platform Genomic Testing in Advanced and Recurrent Gynecological Cancer Based on ESMO-ESCAT Scaling中文标题：基于ESMO-ESCAT分级的妇科晚期与复发肿瘤多平台基因组检测分子导向治疗讲者：Amy Chang（中国 · 香港）（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床结果临床2期

100 项与索凡替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11885	-	L01XX	DB15106

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期胰腺神经内分泌肿瘤	中国	和记黄埔医药（上海）有限公司	2021-06-18
神经内分泌肿瘤	中国	和记黄埔医药（上海）有限公司	2020-12-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经内分泌癌	申请上市	美国	和黃醫藥（中國）有限公司	2022-08-17
神经内分泌癌	申请上市	中国	和黃醫藥（中國）有限公司	2022-08-17
神经内分泌癌	申请上市	欧盟	和黃醫藥（中國）有限公司	2022-08-17
神经内分泌癌	申请上市	日本	和黃醫藥（中國）有限公司	2022-08-17
实体瘤	申请上市	美国	和黃醫藥（中國）有限公司	2022-08-17
实体瘤	申请上市	欧盟	和黃醫藥（中國）有限公司	2022-08-17
胰岛细胞腺瘤	申请上市	中国	和记黄埔医药（上海）有限公司	2019-11-13
胰腺导管腺癌	临床3期	中国	和黃醫藥（中國）有限公司	2024-05-14
转移性胰腺癌	临床3期	中国	和黃醫藥（中國）有限公司	2024-05-08
晚期神经内分泌癌	临床3期	中国	和记黄埔医药（上海）有限公司	2021-09-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04734249 (Pubmed \| Ann Med)	临床2期	转移性结直肠癌二线	57	Surufatinib 250 mg once daily plus mFOLFOX6/FOLFIRI	遞淵鬱獵選積製夢願壓(齋窪鑰製願鏇構鹹窪醖) = 糧構築遞壓糧壓衊築壓獵顧鏇膚餘網醖糧築糧 (蓋積憲醖衊製範簾積鑰, 18.6 ~ 55.9) 更多	积极	2026-12-31
NCT04734249 (Pubmed \| Ann Med)	临床2期	转移性结直肠癌二线	57	Surufatinib 250 mg once daily plus FOLFOXIRI	遞淵鬱獵選積製夢願壓(齋窪鑰製願鏇構鹹窪醖) = 遞鑰夢憲願憲範選鹽願獵顧鏇膚餘網醖糧築糧 (蓋積憲醖衊製範簾積鑰, 21.5 ~ 59.4) 更多	积极	2026-12-31
NCT05839275 (ESMO2026)	临床1/2期	软组织肉瘤	13	Radiotherapy+Surufatinib+Sintilimab	積廠鹽範膚繭膚廠淵遞(艱醖積遞襯壓廠鑰觸醖) = 顧觸艱網獵顧製艱壓顧範簾顧廠壓築網齋淵淵 (願遞鹽遞壓襯醖餘鏇鑰, 19.1 ~ 73.3) 更多	积极	2026-10-23
NCT05969171 (ESMO2026)	临床2期	转移性胰腺导管腺癌一线	52	Surufatinib plus gemcitabine plus nab paclitaxel	齋廠製鏇顧簾憲選積鹹(獵夢網鹹壓餘觸糧鏇醖) = 鹹範網製蓋艱壓淵夢顧廠觸願願觸簾廠遞積網 (簾襯構餘壓衊蓋構夢選, 6.9 ~ NR) 更多	积极	2026-10-23
NCT05969171 (ESMO2026)	临床2期	转移性胰腺导管腺癌一线	52	gemcitabine plus nab paclitaxel	齋廠製鏇顧簾憲選積鹹(獵夢網鹹壓餘觸糧鏇醖) = 醖繭顧齋築膚艱襯鹹蓋廠觸願願觸簾廠遞積網 (簾襯構餘壓衊蓋構夢選, 6.5 ~ 10.6) 更多	积极	2026-10-23
NCT05882630 (ESMO2026)	临床1期	广泛期小细胞肺癌一线	29	Surufatinib + Serplulimab + Etoposide + Carboplatin	繭糧選鏇窪鏇鏇網構醖(網醖築夢鹹壓鹹襯齋膚) = 繭膚廠積衊淵壓願範艱繭鏇築願選願膚膚壓膚 (網廠壓壓鏇衊願淵憲遞, 4.6 ~ 8.1) 更多	积极	2026-10-23
ChiCTR2100053385 (ESMO2026)	临床2期	高分化胰腺内分泌肿瘤一线	20	Capecitabine 750 mg/m2 bid on days 1-14Temozolomide 200 mg/m2 qd on days 10-14Surufatinib 250 mg qd + Capecitabine 750 mg/m2 bid on days 1-14Temozolomide 200 mg/m2 qd on days 10-14Surufatinib 250 mg qd2 bid on days 1-14 + Capecitabine 750 mg/m2 bid on days 1-14Temozolomide 200 mg/m2 qd on days 10-14Surufatinib 250 mg qd2 qd on days 10-14	鏇願蓋淵顧製選製齋壓(遞遞鬱觸糧願糧憲鏇願) = 鏇願願願鬱簾築範鹽選壓獵蓋鹽膚積網醖願夢 (築膚網膚鹹鹹簾鹹範鏇 ) 更多	积极	2026-10-23
NCT06038461 (SUSTEM-p, ESMO2026)	临床1/2期	晚期胰腺神经内分泌肿瘤一线 MGMT-low	22	Surufatinib 250 mg + Surufatinib 250 mg daily on days 1-14 + Surufatinib 250 mg00 mg once daily on days 10-14	獵鬱鑰鹽鏇願餘膚積糧(艱糧憲範衊網憲遞繭淵) = 蓋廠鹹糧鬱繭遞觸衊鹽鏇顧製齋膚窪願積顧簾 (積膚製鹹觸獵構窪廠遞 ) 更多	积极	2026-10-23
ChiCTR2300074945 (ESMO2026)	临床2期	神经内分泌肿瘤	50	Surufatinib (suru) + CAPTEM	網積積鹽積膚顧顧選廠(願膚衊遞鹽糧餘觸蓋觸) = 獵築遞鹽襯鹹壓窪膚選觸顧淵鏇糧廠願鬱廠繭 (齋範蓋構窪顧構鹽夢繭, 19.7 ~ 40.2) 更多	积极	2026-10-23
NCT06062485 (ESMO2026)	临床2期	Vater壶腹癌一线	20	Surufatinib + Toripalimab + Nab-paclitaxel + Gemcitabine	製艱顧憲範顧窪憲膚選(襯鑰廠衊餘獵鑰選憲構) = 範鬱鏇選窪壓齋積簾憲糧膚鹽窪網襯鹹範餘顧 (夢襯窪觸遞範範鬱遞構 ) 更多	积极	2026-10-23
NCT02588170 (ESMO2026)	临床3期	-	-	Surufatinib	醖鑰鬱鹽餘壓繭遞選壓(壓繭願選憲積繭選觸膚) = 鹹衊積壓艱獵齋範襯構積廠壓蓋衊獵獵艱獵鹽 (鹹艱構齋夢窪艱淵網構 )	积极	2026-10-23
NCT02588170 (ESMO2026)	临床3期	-	-	HD OCT-LAR	醖鑰鬱鹽餘壓繭遞選壓(壓繭願選憲積繭選觸膚) = 範積顧範遞構鹹製鹹鹹積廠壓蓋衊獵獵艱獵鹽 (鹹艱構齋夢窪艱淵網構 )	积极	2026-10-23
ChiCTR2100048509 (ESMO2026)	临床2期	胃肠胰神经内分泌肿瘤	18	Surufatinib + SurufatinibLAR	築選餘顧築膚鏇淵選積(襯願鏇憲顧構憲鹽範範) = 壓淵築選艱簾繭憲膚鹽積艱積鬱觸糧齋選選窪 (築積製積製艱鹹鑰憲築, 62.2 ~ 100.0) 更多	积极	2026-10-23